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Elevated urinary albumin excretion in patients with type 1
diabetes reverts to normoalbuminuria in a majority of
patients but advances toward proteinuria in some. In order to
gain valuable insights into the early pathophysiology of
diabetic nephropathy we evaluated the association of kidney
tubular injury biomarkers with changes in albuminuria in
patients with type 1 diabetes mellitus. Urine levels of kidney
injury molecule-1 (KIM-1), N-acetyl-b-D-glucosaminidase
(NAG), and some inflammatory markers were determined in
38 healthy individuals and 659 patients with type 1 diabetes
mellitus having varying degrees of albuminuria. Urinary
interleukin-6, CXCL10/IP-10, NAG, and KIM-1 levels were very
low in healthy individuals, increased in type 1 patients with
normoalbuminuria, and were highest in diabetic patients that
had microalbuminuria. Low baseline concentrations of
urinary KIM-1 and NAG both individually and collectively
were significantly associated with the regression of
microalbuminuria over the subsequent 2 years; an effect
independent of clinical characteristics. Progression and
regression of microalbuminuria were unrelated to urinary
levels of interleukins 6 and 8, CXCL10/IP-10, and monocyte
chemoattractant protein-1. Thus our results show that lower
urinary KIM-1 and NAG levels were associated with the
regression of microalbuminuria in type 1 diabetes mellitus.
Hence, tubular dysfunction is a critical component of the
early course of diabetic nephropathy.
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Diabetic nephropathy (DN) is the most common cause of
chronic kidney failure and end-stage kidney disease in the
world. An estimated 20.8 million people (7% of the
population) in the United States have diabetes, and nearly
180,000 people are living with kidney failure as a result of
diabetes.1
The earliest known noninvasive biomarker for diagnosis
of DN is microalbuminuria (MA).2 MA in type 1 diabetic
patients is often considered the first inexorable step toward
progression to macroalbuminuria, overt proteinuria, and
end-stage renal failure.2–4 Recent prospective studies,
however, have shown that the elevated urinary albumin
excretion in patients with type 1 diabetes regresses to
normoalbuminuria in a majority and advances toward
proteinuria in only a minority of patients.5 Identifying
sensitive biomarkers that can predict the course of MA
will facilitate early diagnosis and prognosis and guide
interventional strategies. Furthermore, biomarkers that are
informative may provide valuable insights into the early
pathophysiology of DN.
Progressive glomerular dysfunction is traditionally
thought to be the primary mechanism for increase in urine
protein excretion; however, tubulointerstitial disease may
have an important role in pathogenesis and progression of
DN.6–9 Although it has been proposed that renal proximal
tubule injury and dysfunction could be important in the early
increases in urine albumin excretion, this issue has not been
adequately investigated due to lack of sensitive tests of
proximal tubule injury in humans.10,11 It is also important
to recognize that albuminuria is a marker of tubular injury
in addition to increases in glomerular permeability. In fact,
the US Food and Drug Administration and the European
Medicines Agency have qualified urinary albumin as a
biomarker of tubular injury with nephrotoxins.12
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Because tubular injury markers can provide important
insight into the status of the proximal tubule in humans and
because it is known that an inflammatory component is
involved in the DN in type 1 diabetes mellitus (DM),9,13,14
the primary objective of this study was to evaluate the
behavior of sensitive biomarkers of tubular injury and
inflammation relative to albumin excretion early in the
course of type 1 diabetes.
Kidney injury molecule-1 (KIM-1) is a type 1 cell
membrane glycoprotein, which contains, in its extracellular
portion, immunoglobulin- and mucin-like domains, with N-
and O-glycosylation sites. KIM-1 expression is undetectable
in normal kidneys but the mRNA and protein are markedly
upregulated with acute kidney injury.15–18 KIM-1 is expressed
on the apical membrane of proximal tubule cells and its
ectodomain is cleaved and released into the lumen of the
tubule ultimately appearing in the urine where it is stable.
KIM-1 is a highly sensitive and specific biomarker for
proximal tubule injury because of a wide variety of
pathophysiological states and toxins in animals and hu-
mans.19–25 N-acetyl-b-D-glucosaminidase (NAG) is a 140 kDa
proximal tubular brush border lysosomal enzyme, which is
released into the urine after renal proximal tubule injury.23,26
Specifically the goals of this study were to compare and
evaluate an association between abnormalities in urinary
albumin excretion and urinary concentrations of tubular
injury markers, KIM-1 and NAG, and tubular inflammatory
markers interleukin-6 (IL-6), interleukin-8 (IL-8), CXCL10
(formerly referred to as IP-10), and monocyte chemoattrac-
tant protein-1 (MCP-1) using data on longitudinal changes
in urinary albumin excretion that were obtained in the large
Second Joslin Study on Natural History of Microalbuminuria
in type 1 diabetes.
RESULTS
Cross-sectional study
The study groups consisted of 363 patients with type 1
diabetes and normoalbuminuria (DM-NA group), 296
patients with type 1 diabetes and microalbuminuria
(DM-MA group), and 38 healthy nondiabetic individuals
(controls). Clinical characteristics, baseline concentration of
urinary chemokines, and markers of tubular injury in the
study groups are shown in Table 1. Patients in the DM-MA
group were more likely to be male, slightly older, with longer
diabetes duration, higher serum hemoglobin A1c (HbA1c)
and, by design, higher albumin-to-creatinine ratio (ACR)
compared with patients in the DM-NA group. Individuals in
the control group were slightly older, and by design had low
HbA1c and low ACR in comparison with the DM-NA group.
Urinary concentrations of the chemokines, IL-6 and IP-10,
and markers of tubular injury, NAG and KIM-1, were
significantly different among the three groups. Concentra-
tions were the lowest in the control group, increased in the
DM-NA group, and were highest in the DM-MA group. The
differences between the controls and DM-NA group and
between the DM-NA and DM-MA groups were highly
significant for both KIM-1 and NAG. Among urinary
chemokines, the differences reached the level of statistical
significance only for IL-6, IP-10, and MCP-1 when the DM-
MA group was compared with the DM-NA group.
Follow-up study of patients with MA
A total of 296 patients in the DM-MA group were followed
for a 2-year interval. MA regressed in 71 patients (24%),
remained stable in 188 patients (63.5%), and progressed in 37
individuals (12.5%). The median values of albumin excretion
rate (AER) at the end of the 2-year follow-up were as follows:
Table 1 | Clinical characteristics and concentrations at baseline of urinary chemokines and urinary markers of tubular injury
according to the study group
Patients with type 1 diabetes
Clinical
characteristics Controls (n=38)
Normoalbuminuria
(DM-NA) (n=363)
Microalbuminuria
(DM-MA) (n=296)
P-value, controls
vs DM-NA
P-value, DM-MA
vs DM-NA
Age (years) 43±10 39±12 41±12 0.025 0.009
Gender (% male) 50 44 61 NS o0.0001
Duration (years) NA 20+9 23+10 NA o0.0001
HbA1c (g%) 5.3±0.4 8.3±1.2 8.6±1.5 o0.0001 0.006
AER (mg/min) 10 (7–15) 14 (10–19) 67 (41–124) o0.0001 Different by design
Urinary chemokines
IL-6 (ng/g cr) 0.20 (0.00–0.55) 0.48 (0.21–1.45) 0.63 (0.27–1.69) 0.0002 0.007
IL-8 (ng/g cr) 0.3 (0.0–7.1) 1.8 (0.3–8.5) 2.1 (0.5–12.5) 0.014 0.19
IP-10 (ng/g cr) 2.3 (1.3–9.3) 7 (2–29) 21 (8–55) 0.010 o0.0001
MCP-1 (ng/g cr) 38 (10–71) 42 (19–75) 59 (33–92) 0.24 o0.0001
Urinary markers of tubular injury
NAG (U/g cr) 0.6 (0.1–1.2) 2.0 (1.2–3.5) 3.4 (2.0–5.7) o0.0001 o0.0001
KIM-1 (ng/g cr) 21 (2–46) 29 (13–73) 60 (29–133) 0.008 o0.0001
Abbreviations: AER, albumin excretion rate; DM-MA, type 1 diabetes and microalbuminuria; DM-NA, type 1 diabetes and normoalbuminuria; KIM-1, kidney injury molecule-1;
MCP-1, monocyte chemoattractant protein-1; NAG, N-acetyl-b-D-glucosaminidase; NS, not significant.
Clinical characteristics are presented as mean±standard deviation except for AER: median (25–75th percentile). Urinary markers with creatinine adjustment presented as
median (IQR). Urinary markers and AER log-transformed for the purpose of the statistical analysis. t-Test and w2-test with continuity correction were used for the comparison
between appropriate groups.
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22 (15–35) mg/min for the MA regression group, 72
(44–130) mg/min for MA stable group, and 324 (195–612)
mg/min for the MA progression group.
The characteristics of the patients according to changes
in AER during the follow-up are presented in Table 2.
Subjects did not differ in regards to age, diabetes duration,
glomerular filtration rate, and blood pressure (BP) measures.
Patients with MA regression in comparison with MA
progression group had lower AER and HbA1c values and
were slightly more frequently treated with ACE inhibitors,
but did not differ by the frequency of the other antihyper-
tensive treatment.
Urinary markers and regression and progression of MA
Table 3 shows the median (25th, 75th percentiles) concentra-
tions of baseline and follow-up urinary markers normalized
to urinary creatinine concentration as they relate to AER
changes over the 2-year follow-up in the DM-MA group.
Patients in each of the groups: MA regression, MA stable and
MA progression, did not differ with regard to base-
line urinary concentrations of IL-6, MCP-1, or IP10. IL-8
concentrations differ among the groups, but the effect did
not parallel the increase in AER in a linear pattern. Patients in
the MA regression group had significantly lower urinary
concentrations of tubular markers, NAG and KIM-1, than
subjects in the MA stable group, and also NAG had a
tendency to lower values in comparison of MA regression vs
progression. Figure 1a and b shows the percent of subjects in
which MA regressed during 2-year follow-up in the DM-MA
study group according to quartiles of urinary concentrations
of NAG and KIM-1 at baseline. MA regression was frequent
in patients with low levels of NAG or KIM-1 at baseline. For
the MA regression, the effect of NAG was proportional across
quartiles whereas effect of KIM-1 was the most pronounced
for Q1. The frequency of MA regression declined with
increased baseline urinary levels of NAG (test for trend
P¼ 0.0009). A total of 39% of patients with urinary NAG at
baseline in quartile 1 (NAG Q1o2.0U/g cr) experienced MA
regression, whereas albuminuria decreased in only 16% of
patients if baseline urinary NAG levels were in quartile 4
(NAG Q445.71U/g cr). Similarly, 36% subjects with low
urinary KIM-1 (Q1 o29 ng/g cr) had regression of MA, in
comparison with only 18% of subjects with high KIM-1
(Q44132 ng/g cr) in which MA regressed. The odds of MA
regression were 4.8 (95% CI 1.9–12.7) and 2.6 (95% CI
1.1–6.1) for NAG Q1 or KIM-1Q1 in comparison with high
levels (Q4) of the markers (Table 4). The effect of NAG and
KIM-1 on regression of MA was independent from other
clinical characteristics, as the odds ratio hardly changed after
adjustment for such characteristics as age, gender, AER,
hemoglobin A1c, systolic BP, renoprotective treatment, and
serum cholesterol levels (Table 4). Crude and adjusted
analysis of the associations of NAG and KIM-1 with MA
course, performed without creatinine adjustment, yielded
comparable results.
DISCUSSION
Although MA has been proposed to be an early predictive
biomarker of DN, it is clear that in the majority of patients
MA can regress to normoalbuminuria and in a minority it
progresses to proteinuria.5 Although MA has generally been
attributed to glomerular injury, nephrotoxicity studies in
Table 2 | Baseline clinical characteristics according to changes in microalbuminuria during 2 years of follow-up
Changes in microalbuminuria during 2-year follow-up P-value
Clinical characteristics
at baseline
MA Regression
(n=71)
MA Stable
(n=188)
MA Progression
(n=37)
Regression vs
stable
Progression vs
stable
Progression vs
regression
Age (years) 40+12 42+11 38+14 NS 0.07 NS
Gender (% male) 37 (52) 126 (67) 17 (46) 0.03 0.03 NS
Duration (years) 24+9 23+10 21+9 NS NS NS
AER (mg/min) 65 (46–108) 66 (44–134) 108 (49–150) NS 0.06 0.024
CcGFR (ml/min per 1.73m2) 101+24 98+27 96+32 NS NS NS
Systolic BP (mmHg) 124+13 125+14 123+13 NS NS NS
Diastolic BP (mmHg) 74+8 73+8 73+7 NS NS NS
HbA1c (g%) 8.3+1.5 8.6+1.4 9.0+1.9 NS NS 0.03
Cholesterol (mg/dl) 194+29 188+30 200+33 NS 0.03 NS
ACEi Tx, n (%) 70 62 43 NS 0.05 0.011
Anti-Hyp Tx, n (%) 30 20 22 NS NS NS
Current smokers, n (%) 14 21 14 NS NS NS
Abbreviations: AER, albumin excretion rate; BP, blood pressure; GFR, glomerular filtration rate; MA, microalbuminuria; NS, not significant.
MA regression, defined as 50% decrease in AER (averaged value from 2-year follow-up interval) in reference to 2-year interval preceding baseline measurements.
MA progression, defined as 100% increase in AER.
Continuous variables reported as mean±s.d. except for AER where median (IQR) was used.
AER, median albumin excretion rate of all AER determination carried out during the 2-year interval preceding the baseline examination.
CcGFR, estimated GFR based on serum cystatin C concentration according to Macisaac et al.39 formula.
HbA1c, mean value of multiple measurements of HbA1c carried out during the 2-year interval preceding the baseline examination.
AER was log10 transformed for the purpose of the statistical analysis.
P-value represents significance of analysis of variance for unbalanced design for all variables except for categorical covariates where w2-test with continuity
correction was applied.
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animals reveal that albuminuria is a sensitive marker of early
tubular toxicity.12 It is therefore possible that the early MA
observed in many patients with type 1 diabetes may be
partially due to tubular injury resulting from hyperglycemia
and other metabolic factors. The degree of tubular injury
may be associated with more favorable albuminuria outcome.
We evaluated biomarkers that specifically measure tubular
cell injury with the hypothesis that this injury may have a role
in the development and progression/regression of MA in type
1 diabetes.
Using the clinical and albuminuria data from the Second
Joslin Study, we found, in a cross-sectional comparison, that
urinary levels of tubular injury biomarkers KIM-1 and NAG
were significantly elevated in patients with type 1 diabetes
and MA in comparison with diabetics with normoalbumi-
nuria and nondiabetic healthy controls. Low urinary KIM-1
and NAG at baseline were strongly associated with regression
of MA during a 2-year follow-up and the effect was
independent of clinical characteristics.
To the best of our knowledge this is the first prospective
study showing the association between urinary excretion of
very specific tubular injury biomarkers and time-dependent
changes in MA in patients with type 1 diabetes. Our findings
Table 3 | Concentration of urinary markers at baseline according to changes in microalbuminuria during 2 years of follow-up
Changes in microalbuminuria during 2-year follow-up P-value
Biomarkers
MA Regression
(n=71)
MA Stable
(n=188)
MA Progression
(n=37)
Regression vs
stable
Progression vs
stable
Progression vs
regression
Urinary chemokines
IL-6 (ng/g cr) 0.7 (0.2–1.7) 0.6 (0.3–1.6) 0.6 (0.3–1.9) NS NS NS
IL-8 (ng/g cr) 2.2 (0.9–19.2) 1.9 (0.5–7.2) 6.5 (0.9–63.4) 0.04 0.007 NS
IP10 (ng/g cr) 18 (7–45) 23 (8–52) 33 (14–65) NS NS NS
MCP-1 (ng/g cr) 60 (30–88) 58 (33–95) 62 (47–92) NS NS NS
Urinary markers of tubular injury
NAG (U/g cr) 2.8 (1.7–4.1) 3.8 (2.2–6.1) 3.4 (2.2–5.7) 0.005 NS 0.06
KIM-1 (ng/g cr) 44 (18–109) 61 (34–136) 77 (23–186) 0.026 NS NS
Abbreviations: KIM-1, kidney injury molecule-1; MA, microalbuminuria; MCP-1, monocyte chemoattractant protein-1; NAG, N-acetyl-b-D-glucosaminidase; NS, not significant.
Median (25th, 75th percentile) levels of urinary markers adjusted for creatinine are presented in the table.
They were log10 transformed for the purpose of the analysis. P value represents analysis of variance for unbalanced design.
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Figure 1 | Frequency of MA regression during the 2-year
follow-up as a function of creatinine-normalized urinary
concentrations of markers of tubular injury. In (a and b) the
proportion of subjects who regressed is plotted as a function of
baseline quartiles of NAG and KIM-1. MA: microalbuminuria; Q1, Q2,
Q3, Q4: quartiles 1–4, respectively. Quartile ranges: NAG, Q1o2.0,
Q2 2.0–3.4, Q3 3.4–5.6, Q445.7 (U/g cr); KIM-1, Q1o29, Q2 29–60,
Q3 60–132, Q44132 (ng/g cr). P-values for a test of trend are
presented.
Table 4 | Effect of the salutary (low) levels of NAG and KIM-1
at the baseline on MA regression
Crude model Adjusted model
Biomarkers OR (95% CI) P-value OR (95% CI) P-value
NAG
Q1 vs Q4 3.4 (1.5–7.6) 0.003 4.8 (1.9–12.7) 0.0013
Q2 vs Q4 1.8 (0.7–4.1) 0.20 2.3 (0.9–6.3) 0.089
Q3 vs Q4 1.1 (0.5–2.7) 0.81 1.5 (0.5–4.2) 0.45
Q4 REF 1.0 REF 1.0 REF
KIM-1
Q1 vs Q4 2.6 (1.2–5.8) 0.019 2.6 (1.1–6.1) 0.03
Q2 vs Q4 1.3 (0.6–3.0) 0.55 1.0 (0.4–2.6) 0.95
Q3 vs Q4 1.4 (0.6–3.2) 0.47 1.3 (0.5–3.4) 0.52
Q4 REF 1.0 REF 1.0 REF
Quartiles (Q1, Q2, Q3, Q4) based on the creatinine-adjusted values. Quartile ranges:
NAG, Q1o2.0, Q2 2.0–3.4, Q3 3.4–5.6, Q445.7 (U/g cr); KIM-1, Q1o29, Q2 29–60, Q3
60–132, Q44132 (ng/g cr). P-value for the crude and adjusted logistic regression
models. Adjusted model controlled for age, gender, AER, hemoglobin A1c, systolic
BP, renoprotective treatment, and serum cholesterol levels.
NAG and KIM-1 concentrations were markedly correlated (Spearman’s rank
coefficient r=0.55, Po0.0001); nevertheless the effect of NAG Q1 and of KIM-1 Q1
remained significant when they were both entered in the adjusted model, resulting
with OR: NAG Q1 vs Q2–Q4 2.8 (1.4–5.6) and KIM-1 Q1 vs Q2–Q4 2.1 (1.1–4.0),
respectively.
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provide strong evidence that tubular injury is an important
component of the natural history of MA in type 1 diabetes.
Less injury to the proximal tubule, as reflected by lower levels
of urinary KIM-1 and NAG, is associated with regression
of MA independently from glycemic control, or BP, or
treatment with ACE inhibitors. There has been a great deal
of focus on the role of proteinuria and progression of
tubulointerstitial damage,27 and it is well appreciated that
tubulointerstitial scarring is the best predictor of renal
outcome in diabetic and nondiabetic renal disease. Tubu-
lointerstitial disease has been proposed to be secondary to
both enhanced protein uptake by proximal tubule cells with
lysosomal rupture resulting in direct tubule toxicity as well as
cytokines and chemokines generated by the proximal tubule
after albumin uptake, which enhance the inflammatory
response and activate fibrotic processes in the interstitial
compartment.28 It is possible, however, that proximal tubule
injury is primary rather than secondary in the development
of MA. In an attempt to identify early urinary biomarkers of
nephrotoxicity the Predictive Safety Testing Consortium
tested many proximal tubule toxins in rats and found that
MA was a excellent biomarker for tubular injury.12 The fact
that cultured proximal29 and interstitial30 cells respond directly
to high levels of glucose with production of profibrotic
mediators also supports the concept that tubulointerstitial
disease may be primary rather than secondary in DM.
Although there is some controversy over how much protein is
filtered in a normal kidney,31 it is generally agreed upon that
there is some normally filtered albumin that is reabsorbed by
the proximal tubule. If this reabsorption is impaired, we
would expect to see MA; therefore, the earliest kidney lesion
in type 1 DM may be tubular injury, not glomerular injury.
We propose an important role for urinary NAG and
KIM-1 for the diagnosis and monitoring of the course of
renal disease in DM. As a lysosomal enzyme, urinary NAG
elevation would be expected to be enhanced with proximal
tubule injury although it may also be increased because of
enhanced lysosomal activity without injury, per se.23 NAG has
been extensively studied in both the adult and pediatric
populations and has proven to be a sensitive, persistent, and
robust indicator of proximal tubule injury.23 Many studies
have established that the KIM-1 ectodomain serves as a very
reliable biomarker of kidney injury both in rodents and in
humans in which the data suggest it is not only a sensitive
indicator of injury but can be a predictive biomarker of
outcome.6,18,23,32 We have reported recently an algorithm
using four biomarkers, including KIM-1 and NAG, to
identify optimally acute kidney injury in hospitalized
patients.23
IL-6, IL-8, IP-10, and MCP-1 have been previously
implicated in the development of DN, renal function decline,
and chronic inflammation.9,33 Although elevated levels of
markers in urine indicative of low-level inflammation were
specific for early progressive renal function decline, none of
them was associated with MA in a previous study.9
Consistent with these prior results the present study shows
that patients with MA had significantly higher levels of IL-6,
IP-10, and MCP-1 levels when compared with patients with
normoalbuminuria. In no case, however, were changes in one
of these urinary cytokine levels associated with progression or
regression of MA.
One of the limitations of this study is the small number of
patients who had MA progression, thereby preventing
adequate evaluation of biomarkers associated with MA
progression. In addition, the follow-up period was only
2 years and hence too short to adequately determine the
potential of urinary KIM-1 and NAG to predict permanent
regression or progression of MA. Because this study was
focused on the relationship between proximal tubule injury
and MA early in type 1 DM, it does not establish the
relationship of urinary tubular injury biomarkers with
changes in glomerular filtration rate over time. It is possible
that the findings in patients with advanced proteinuria may
be different, and findings in type 1 DM may not be
generalized to patients with type 2 DM and MA. Nevertheless
this study provides important new insight into the im-
portance of proximal tubule injury with associated MA early
in the course of type 1 DM and identifies proximal tubule
injury biomarkers that, when at low levels are associated with
reduction in albuminuria over a 2-year follow-up period. It is
possible, for example, that MA in the absence of significant
tubule injury may inflict a functional state that is more readily
reversible. This may relate to reversible changes in glomerular
hemodynamics, for example.
In summary, the results of our study show that low
urinary levels of KIM-1 and NAG are associated with
regression of MA in type 1 diabetes and suggest that tubular
dysfunction is a critical component of the early course of DN.
METHODS
Study populations
Nondiabetic subjects. For comparison of diabetic patients with
nondiabetic subjects, we recruited a control group that consisted of
38 healthy individuals without any history of diabetes, kidney
disease, hypertension, or other serious comorbidities and compar-
able in age to the type 1 DM group. These individuals were recruited
and examined during a family study on the genetics of type 2
diabetes carried out at the Joslin Clinic, Boston, MA.
Type 1 diabetic subjects. The study groups with diabetes
consisted of patients without overt proteinuria who were enrolled
into the Second Joslin Study on the Natural History of Micro-
albuminuria (Second Joslin Kidney Study). Detailed descriptions of
the Joslin Clinic population and the recruitment protocol for
Second Joslin Kidney Study have been published previously.34
Briefly, between 1 January 2003 and 31 December 2004 patients with
type 1 DM cared for at the Joslin Clinic were recruited into the
Second Joslin Kidney Study. Eligibility criteria included residence in
New England, diabetes diagnosed before age 40 years, treatment
with insulin, current age 18–64 years, diabetes duration 3–39 years,
and at least two measurements of HbA1c and urinary ACR during a
baseline 2-year interval. Exclusion criteria included advanced DN
(proteinuria or end-stage renal disease), or other serious comorbid-
ities including nondiabetic kidney disease, HIV, or HCV infection,
or extreme obesity (body mass index 440 kg/m2).
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Enrollment and examination
Trained recruiters administered a structured interview and brief
examination to eligible patients at a routine visit to the clinic. This is
termed ‘the entry examination.’ The interview solicited the history
of diabetes and its treatment, other health problems, use of
medications, and self-reports of height and weight. Current and
past use of medications (particularly ACE inhibitors, angiotensin II
receptor blockers, and other antihypertensive drugs) was recorded.
The recruiter measured seated BP twice (in the 5-min interval) using
an automatic monitor (Omron Healthcare, Vernon Hills, IL), and
obtained samples of blood and urine. Details of the assays used were
described previously.35,36 For characterizing patients’ baseline
exposures, repeated measures in the 2 years up to and including
entry examination were summarized by their mean values (HbA1c,
cholesterol).
Assessment of urinary albumin excretion
Albumin-to-creatinine ratio was measured in multiple random
urine samples in the ‘baseline’ 2 years up to and including entry
examination (at least three measurements). Subsequently, to
determine baseline albuminuria status, ACR measurements were
converted to AER according to a formula published previously.37
Individuals with the median of all available AER measurements
in the range 30–300 mg/min were classified as DM-MA group and
those with albumin excretion lower than 30 mg/min were regarded
as the DM-NA (normoalbuminuria) group. Patients with AER
X300 mg/min were considered as having proteinuria and were
excluded from the study.
AER follow-up study
Individuals with type 1 diabetes and MA (DM-MA group) at
baseline (n¼ 296) were followed for the next 2 consecutive follow-
up years. Albumin excretion was determined within this follow-up
interval based on a median of 3 (range 2–6) measurements of ACR
and converted to AER using the same formula as for baseline
measurements. Regression of MA (MA regression group) was
defined as at least a 50% reduction in albumin excretion from
baseline. Progression of MA (MA progression group) was defined as
increase in AER by 100% or more over baseline. MAwas regarded to
be stable over time (stable MA group) if values of AER decreased by
o50% or increasedo100%. These definitions have previously been
implemented.5
Urine collection for biomarkers
Urine samples were collected at the baseline examination at a single
time point. All urine specimens for the measurements of the
markers were handled in the same way. Patient specimens were
collected into sterile cups (Vacutainer Urine Collection Cup;
Cardinal Health, Dublin, OH) during the daytime and then
aliquotted into 1.5ml volumes into sterile, nontoxic, nonpyrogenic
cryogenic tubes (CryoTubes CryoLine System; NUNC Serving Life
Science, Rochester, NY), and frozen at 80 1C until further analysis.
Measurement of urinary biomarkers
Urine samples were thawed, vortexed and centrifuged, and
biomarker measurements were performed on the supernatant.
Urinary NAG was measured spectrophotometrically according to
the manufacturers’ protocols (Roche Diagnostics). Urinary
KIM-1, IL-8, IP-10, and MCP-1 measurements were performed
using microsphere-based Luminex xMAP technology as described
previously.9,23 This is a multiplex particle-enhanced, sandwich type,
liquid-phase immunoassay with laser-based detection system based
on flow cytometry.38 The assay to measure KIM-1 was developed
and evaluated in our laboratory23 whereas Beadlyte Human Multi-
Cytokine Detection (48-011) (Upstate-Millipore, Billerica, MA)
with protocol B was used to measure IL-8, IP-10, and MCP-1. Urine
samples (25 ml for IL-8, IP-10, and MCP-1 or 30 ml for KIM-1) were
analyzed in duplicate and respective analytes were quantitated using
8-point (or 13-point for KIM-1 assay) five parametric logarithmic
standard curves. The inter- and intraassay variability waso20% for
all assays. Urinary IL-6 was measured by enzyme-linked immuno-
sorbent assay (high sensitive immunoassay: HS600B; R&D,
Minneapolis, MN) according to the manufacturer’s protocol.9 The
urinary levels of the respective antigens were expressed in absolute
terms and also normalized to the urinary creatinine concentration.
Investigators who were unaware of the patients’ clinical characteristics
performed all of the urinary analyte measurements. All the urine
specimens for the measurements of the markers had the same
number of freeze–thaw cycles (two freeze–thaw cycles).
Statistical analysis
Continuous clinical characteristics were presented as mean±
standard deviation, and the categorical ones as proportion. Urinary
markers normalized to creatinine were presented as median (25th,
75th percentiles). Statistical analysis was performed on creatinine-
normalized and the log-transformed urinary markers. t-Test and
w2-test were used for comparisons between the study groups. In the
follow-up analysis, we categorized the investigated markers into
quartiles to evaluate relationships between levels of the markers and
the odds of regression and progression using logistic regression.
In the adjusted model, adjustment was made for the clinical
characteristics that were significant in the crude analyses or clinically
relevant based on the formerly published reports.5 Clinical
characteristics were considered in two ways: as quartiles and as
strata by formerly assigned clinical cutoffs regarded associated with
MA course (considered cutoff points: HbA1c, 8 g/l; systolic BP,
115mmHg; serum cholesterol level, 198mg/dl; median baseline
ACR, 68mg/g). All analyses were performed using SAS version 9.1
(SAS Institute, Cary, NC). The Committee on Human Subjects of
the Joslin Diabetes Center approved the protocol and informed
consent procedures for this study.
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